Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study.
Marc P BonacaE LesénE GiannitsisJ HedbergT JernbergD LambrelliM DuongA P MaggioniA Ariza-SoléJ Ten BergR F StoreyPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
This study provides insights into the use of ticagrelor 60 mg in patients with prior MI in clinical practice. Observed event rates for ischemic events and bleeding generally align with those in the pivotal trials, support the established safety profile of ticagrelor, and highlight the significant residual ischemic risk in this population.Clinical Trials.gov Registration NCT04568083.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- clinical trial
- st segment elevation myocardial infarction
- clinical practice
- st elevation myocardial infarction
- coronary artery disease
- atrial fibrillation
- ischemia reperfusion injury
- heart failure
- left ventricular
- cerebral ischemia
- randomized controlled trial
- metabolic syndrome
- oxidative stress
- newly diagnosed
- skeletal muscle
- open label
- insulin resistance